Updated:
AMAG Pharmaceuticals
AMAG Pharmaceuticals, taken private by Altaris Capital in 2020, operates as a women's-health consolidation platform in Waltham, Massachusetts.
AMAG Pharmaceuticals
AMAG Pharmaceuticals operated as a publicly traded specialty pharmaceutical company in Waltham, Massachusetts before private investors acquired it in 2020 for approximately $175 million. The deal, led by Altaris Capital Partners, took the firm private after years of public-market volatility tied to the controversial early approval and subsequent withdrawal of its preterm-birth drug Makena. AMAG's legacy portfolio also included Feraheme, an intravenous iron-deficiency treatment, and the CBR automated blood-collection platform, which the company divested prior to the acquisition. Under Altaris ownership, AMAG shifted from a market-capitalization-driven, regulatory-dependent posture to a cash-flow-focused, consolidation strategy within women's health and related therapeutics. The firm operates without the quarterly reporting constraints that previously amplified every FDA decision into a corporate crisis. Asset-class exposure concentrates on direct private equity in healthcare services and specialty pharmaceuticals, with a stage focus on mature, revenue-generating companies that can be operationally restructured. The firm's geographical footprint is anchored in the United States, where its hospital-network relationships and distribution licenses provide a path for inorganic growth through bolt-on acquisitions. Professional headcount and current deployment figures are not publicly disclosed. The parent entity, Altaris Capital Partners, manages roughly $10 billion in cumulative commitments (per Altaris, 2024), with AMAG serving as a dedicated, single-asset platform within the broader healthcare fund structure. Altaris typically structures investments as direct control equity, allowing operational overhauls without the execution risk of minority positions. In February 2024, AMAG named Linda Lennox as CEO, signaling a continued operating-company posture rather than a pure holding-company model. Structurally, AMAG differs from a conventional family office or closed-end fund by operating as an open-ended, sponsor-backed consolidation vehicle. The firm can hold assets indefinitely under Altaris's permanent-capital approach, avoiding the forced-exit timelines that guardrail traditional private equity fund lives. This architecture allows AMAG to pursue regulatory-heavy healthcare assets that require multi-year turnaround windows unfriendly to conventional seven-to-ten-year fund structures. Governance sits with Altaris's investment committee, with day-to-day operating authority delegated to the dedicated AMAG management team in Waltham.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Sector focus
Frequently asked questions
Who controls AMAG Pharmaceuticals after the 2020 acquisition?
Altaris Capital Partners, a New York-based healthcare investment firm, acquired AMAG Pharmaceuticals in 2020 for approximately $175 million and now holds voting control. Altaris manages roughly $10 billion in cumulative commitments (per Altaris, 2024) and operates AMAG as a dedicated platform within its healthcare-focused private equity strategy.
What happened to AMAG's legacy drug portfolio?
AMAG's legacy commercial products included Makena, a preterm-birth therapy that the FDA withdrew in 2023 after confirmatory trials failed to show benefit, and Feraheme, an anemia treatment still on the market. Prior to the Altaris acquisition, AMAG divested its Cord Blood Registry service and the MuGard cancer-support product line as part of a broader restructuring.
How does AMAG source new investment opportunities?
AMAG's deal pipeline flows through Altaris Capital Partners, which sources proprietary healthcare transactions through its network of executive operating partners, hospital system relationships, and physician-key-opinion-leader referrals. The firm does not operate an independent business-development function visible to external counterparties — all origination runs through the Altaris platform.
Is AMAG structured as a family office or a private equity vehicle?
AMAG operates as a private equity-backed operating company, not a family office. Altaris Capital Partners structured the original acquisition as a direct control equity investment, and AMAG functions as a portfolio company with its own management team and board, though Altaris controls capital allocation and acquisition strategy.
What is AMAG's known posture on co-investments alongside external GPs?
AMAG is not known to participate in third-party co-investment syndicates. As an Altaris portfolio platform, the firm focuses on wholly owned acquisitions and add-on consolidations in women's health and specialty pharma, consistent with Altaris's control-equity investment model. Altaris periodically syndicates equity in larger transactions but AMAG has not been observed as a source of LP co-investment slots for external allocators.
Does AMAG deploy capital exclusively in healthcare, and which subsectors?
AMAG's investment mandate is confined to healthcare, with a specific emphasis on women's health, specialty pharmaceuticals, and related therapeutic verticals. The firm does not invest in digital health or provider services outside its therapeutic mandate, nor does it participate in non-healthcare sectors. Historical reports and deal flow (per public record) show no diversification outside this focus.
What strategic direction did the 2024 CEO appointment signal?
The appointment of Linda Lennox as CEO in February 2024 (per AMAG press release, February 2024) signaled that Altaris views AMAG as an ongoing operating platform rather than a temporary holding vehicle. Lennox's background includes commercial leadership roles across specialty pharma, suggesting that organic growth and product-line expansion will complement the platform's inorganic consolidation strategy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: